Your browser doesn't support javascript.
loading
Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial.
Li, Guoming; Yuan, Mei; Li, Haihong; Deng, Changsheng; Wang, Qi; Tang, Yexiao; Zhang, Hongying; Yu, Weisheng; Xu, Qin; Zou, Yuanyuan; Yuan, Yueming; Guo, Jiawen; Jin, Chunming; Guan, Xiangdong; Xie, Fengjie; Song, Jianping.
Afiliación
  • Li G; Institute of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
  • Yuan M; Department of Intensive Medicine, Hongqi Hospital affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang, People's Republic of China.
  • Li H; Department of Intensive Medicine, Hongqi Hospital affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang, People's Republic of China.
  • Deng C; Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
  • Wang Q; Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
  • Tang Y; Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
  • Zhang H; Institute of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
  • Yu W; Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
  • Xu Q; Institute of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
  • Zou Y; Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
  • Yuan Y; Institute of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
  • Guo J; Institute of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China.
  • Jin C; Department of Intensive Medicine, Hongqi Hospital affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang, People's Republic of China.
  • Guan X; Department of Surgical Intensive Care Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China. Electronic address: carlg@163.net.
  • Xie F; Department of Intensive Medicine, Hongqi Hospital affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang, People's Republic of China. Electronic address: mdjxfj1971@126.com.
  • Song J; Institute of Science and Technology Park, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, People's Republic of China; Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. Electronic address: songjp@gzucm.edu.cn.
Int J Antimicrob Agents ; 57(1): 106216, 2021 Jan.
Article en En | MEDLINE | ID: mdl-33152450
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Quinolinas / Artemisininas / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Antimicrob Agents Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Quinolinas / Artemisininas / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Antimicrob Agents Año: 2021 Tipo del documento: Article